en
Scientific article
English

Further Nonvertebral Fracture Reduction Beyond 3 Years for Up to 10 Years of Denosumab Treatment

Published inJournal of Clinical Endocrinology and Metabolism, vol. 104, no. 8, p. 3450-3461
Publication date2019
Abstract

CONTEXT: Evidence for further nonvertebral fracture (NVF) reductions with long-term antiresorptive therapy in osteoporosis is lacking. OBJECTIVE: To evaluate NVF risk reduction in subjects receiving ≤10 years of denosumab treatment. DESIGN: Phase 3, randomized, placebo-controlled, 3-year Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months (FREEDOM) trial (NCT00089791) and its open-label 7-year extension (NCT00523341).

Citation (ISO format)
FERRARI, Serge Livio et al. Further Nonvertebral Fracture Reduction Beyond 3 Years for Up to 10 Years of Denosumab Treatment. In: Journal of Clinical Endocrinology and Metabolism, 2019, vol. 104, n° 8, p. 3450–3461. doi: 10.1210/jc.2019-00271
Main files (1)
Article (Published version)
accessLevelRestricted
Identifiers
ISSN of the journal0021-972X
261views
1downloads

Technical informations

Creation07/26/2019 10:56:00 AM
First validation07/26/2019 10:56:00 AM
Update time03/15/2023 6:06:06 PM
Status update03/15/2023 6:06:05 PM
Last indexation01/17/2024 6:23:39 AM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack